ImmunityBio, Inc.
ANKTIVA
non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for ANKTIVA in non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The conditional marketing authorization was based on results from the QUILT-3.032 study, a single-arm, open-label, multicenter phase 2/3 clinical trial in 100 adults with BCG-unresponsive NMIBC CIS with or without papillary tumors who recei”